Moderna Stock - Analyst targets diverge as key vaccine decisions loom
21.06.2026 - 07:05:12 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 07:04 CET. Details in the imprint.
Moderna (US60770K1034) is back in the Wall Street spotlight as its pipeline beyond COVID-19 draws fresh scrutiny from analysts. Recent coverage highlights sharply diverging views on the stock's fair value and emphasizes upcoming regulatory decisions for key vaccines, according to market commentary from Nasdaq and other outlets.
All news and analysis on Moderna stock
Key figures, regulatory milestones and analyst updates on Moderna are compiled in the company topic hub and on its investor-relations pages.
What recent reports highlight
Analyst and market-data aggregators point to a wide range of 12-month targets for Moderna, from about $45 at the low end to nearly $90 at the consensus level, based on Wall Street estimates compiled by one forecast service. Another commentary points to longer-term projections that extend far higher but remain speculative.
Separately, recent analyst notes summarized by financial news services describe banks such as Jefferies keeping a cautious stance on Moderna shares while acknowledging progress in its non-COVID pipeline, including an mRNA-based seasonal flu candidate and broader respiratory portfolio. These notes typically flag regulatory decisions and commercialization timing as key swing factors for revenue in 2026 and beyond.
Sunday background - how analysts view Moderna
Background pieces in the financial press underline how sharply views differ after the COVID-19 windfall faded. One analysis notes that Moderna stock has more than doubled year to date, even as revenue remains well below pandemic peaks, suggesting expectations for future product approvals are already partly reflected in the price.
At the same time, overview pages summarizing Wall Street opinions show a spread from cautious “Hold” or even “Underperform” ratings to more optimistic stances that see upside if the company executes on its oncology and respiratory vaccine strategies. Overall, the consensus target cited by one data provider is just under $90, with considerable dispersion around that figure.
The product behind the stock
Moderna generates revenue from its messenger RNA technology platform, best known for the Spikevax COVID-19 vaccine, and is working to diversify into seasonal flu, respiratory syncytial virus (RSV), and cancer vaccines, according to its pipeline overview on the company website. The group’s long-term plan centers on turning this platform into a portfolio of commercial vaccines and therapeutics.
Where the stock trades today
Moderna shares (US60770K1034) last closed on Nasdaq at $63.96 on 06/20/2026, according to recent market data from a stock-price service. That price implies a market capitalization in the mid tens of billions of dollars at the current share count.
Key facts on Moderna stock
- Company: Moderna Inc.
- ISIN: US60770K1034
- WKN: A2N9D9
- Ticker: MRNA
- Venue: Nasdaq
- Price (as of 06/20/2026, 22:00 CET): 63.96 USD
- Market cap: around 26 billion USD (as of 06/20/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
